文献速递肾癌与肾肿瘤

临床局限性肾细胞癌肾切除后局部与区域复发的15年单中心经验:预后特征与肿瘤学结局

Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes.
PubMed 文献 · Urology · 2021-04-20

该研究回顾性分析了2004-2018年单中心3038例手术治疗的肾细胞癌患者,其中1895例为临床局限性(cT1-2N0M0),30例(1.6%)出现孤立性局部或区域复发。结论提示局部治疗对选择性患者合适,复发部位数量有助于筛选获益人群。

要点

  • 临床局限性肾癌术后孤立局部/区域复发罕见,本组仅1.6%。
  • 局部治疗后约半数患者可实现「局部治愈」无二次复发。
  • 2个或以上复发部位显著增加二次复发/转移风险(HR=2.22)。

核心结论

  • 局部治疗对选择性局部/区域复发患者合适,近50%接受二次局部治疗者无二次复发且存活。
  • 复发部位数量可用于筛选适合局部治疗或系统/联合治疗的患者。

研究设计与样本

  • 单中心回顾性研究,纳入2004-2018年手术治疗的临床局限性肾细胞癌(cT1-2N0M0)患者。
  • 共3038例手术患者,其中1895例为临床局限性,30例(1.6%)出现无并发转移的孤立局部和/或区域复发。
  • 进行了比较与生存分析。

主要发现

  • 30例孤立局部/区域复发患者,复发中位时间26.5个月(IQR 16-35)。
  • 26例接受局部治疗的患者中,14例(53.8%)在中位随访29.5个月(IQR 12-45)内再次复发。
  • 1年和2年二次无复发生存率分别为60.7%和49.7%。

关键数值与推荐

  • 临床局限性肾细胞癌术后孤立局部/区域复发发生率约1%-3%(原文背景),本组为1.6%。

临床怎么用

  • 对选择性局部/区域复发患者可考虑局部治疗,尤其复发部位单一者。
  • 复发部位数量(≥2个)应纳入治疗决策,考虑系统/联合治疗。

局限性

  • 单中心回顾性研究,样本量小(30例复发患者)。
  • 选择偏倚可能存在,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate outcomes for patients with local recurrence (LR) of clinically localized renal cell carcinoma (RCC) without concurrent systemic metastasis from our institution, an event that occurs rarely (1%-3%) after surgery. LR may be a harbinger of poor outcomes, and the best management of these patients is unclear. MATERIALS/METHODS: We retrospectively reviewed patients surgically treated for clinically localized RCC (cT1-2N0M0) with subsequent LR (in the partial or radical nephrectomy bed) and/or regional recurrence (RR; in the abdomen distant from the direct site of surgery) without concurrent metastasis from our institutional database (2004-2018). Comparative and survival analyses were performed. RESULTS: Out of 3038 total patients, 1895 had clinically localized RCC, with 30 patients (1.6%) having isolated LR/RR. Median time to recurrence was 26.5 months (IQR:16-35). Of 26 patients treated with local therapy, 14 (53.8%) recurred over a median follow-up time of 29.5 months (IQR:12-45). The 1-year and 2-year secondary recurrence-free survival rates are 60.7% and 49.7%, respectively. Two or more sites of locoregional recurrence significantly predicted secondary recurrence/metastasis after local therapy for local recurrence (hazard ratio: 2.22, P= .04). CONCLUSION: Our results suggest local therapy is appropriate for select patients with LR/RR, with almost 50% of patients undergoing a second local therapy remaining alive with "local cure" and no secondary recurrence. The number of sites of recurrence can be used to better select patients that will benefit from local therapy or systemic/combination therapy. This work provides a framework onto which further studies regarding local therapy and locoregional recurrence of RCC can be performed.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ray S, Cheaib JG, Biles MJ, et al. Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. Urology. 2021. PMID: 33864855. doi:10.1016/j.urology.2021.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。